Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Increasing evidence suggests that renal inflammation contributes to the pathogenesis and
progression of diabetic kidney disease (DKD) and that anti-inflammatory therapies might …